CURRENT APPROACHES AND NEW RESEARCH IN
MODERN SCIENCES
International scientific-online conference
99
MENOPAUSE SYMPTOMS, HEALTH EFFECTS, AND WAYS TO
MANAGE SYMPTOMS
Akbarova Shaxodat
University of Business and Science
Student of group 23_01, 2nd year, the rapeutic work direction
Usmonova Feruza Nematjonovna
Scientific advisor:
https://doi.org/10.5281/zenodo.15558950
Annotation:
This article provides a comprehensive, evidence-based
analysis of menopause, a critical biological transition in women’s lives marked
by the cessation of menstrual cycles due to ovarian follicular depletion and
declining estrogen and progesterone levels. It explores the multifaceted
symptoms of menopause, including vasomotor symptoms (hot flashes, night
sweats), mood disturbances, cognitive complaints, and genitourinary syndrome,
which affect 75-85% of women to varying degrees. The long-term health
implications, such as increased risks of osteoporosis, cardiovascular disease,
metabolic disorders, and shifts in cancer risk profiles, are examined in detail,
emphasizing estrogen’s protective roles. Management strategies are thoroughly
discussed, encompassing hormone replacement therapy (HRT), non-hormonal
pharmacological options (e.g., SSRIs, gabapentin), lifestyle interventions
(exercise, diet, smoking cessation), and psychological support (CBT,
mindfulness). The article also addresses complementary therapies
(phytoestrogens, acupuncture) and their variable efficacy, alongside emerging
treatments like neurokinin-3 receptor antagonists. Psychosocial and cultural
influences on the menopausal experience are considered, advocating for shared
decision-making to enhance treatment adherence. This work integrates recent
clinical research and underscores the importance of individualized care to
optimize health outcomes and quality of life during and beyond menopause.
Keywords:
Menopause, perimenopause, vasomotor symptoms, hot flashes,
night sweats, genitourinary syndrome, osteoporosis, cardiovascular disease,
hormone
replacement
therapy,
non-hormonal
treatments,
lifestyle
interventions, cognitive behavioral therapy, phytoestrogens, acupuncture,
shared decision-making, neurokinin-3 receptor antagonists, psychosocial
factors, women’s health.
Menopause represents a pivotal transition in a woman’s life, characterized
by the permanent cessation of menstrual cycles due to the depletion of ovarian
follicular reserves and a consequent decline in estrogen and progesterone
production. Typically occurring between ages 45 and 55, menopause is clinically
CURRENT APPROACHES AND NEW RESEARCH IN
MODERN SCIENCES
International scientific-online conference
100
confirmed after 12 consecutive months without menstruation. This biological
milestone, while a universal aspect of female aging, manifests with a spectrum of
symptoms and health implications that vary widely in intensity and impact. The
physiological, psychological, and social dimensions of menopause necessitate a
comprehensive understanding of its signs, long-term health consequences, and
evidence-based management strategies to optimize women’s health and quality
of life during and beyond this transition. This article provides an in-depth,
scientifically grounded exploration of these facets, emphasizing recent research
and clinical insights to guide effective interventions.
The journey to menopause begins with perimenopause, a transitional phase
that may last several years, during which ovarian function gradually declines,
leading to irregular menstrual cycles and hormonal fluctuations. Estrogen levels
oscillate unpredictably, contributing to a constellation of symptoms that affect
up to 80% of women. Vasomotor symptoms, notably hot flashes and night
sweats, are among the most common, affecting 75-85% of women. Hot flashes
manifest as sudden, intense sensations of heat, often accompanied by sweating,
flushing, and occasionally chills, lasting from 30 seconds to 10 minutes. These
episodes stem from altered hypothalamic thermoregulation, where declining
estrogen levels disrupt the brain’s temperature control mechanisms, triggering
inappropriate heat dissipation responses. Night sweats, occurring during sleep,
exacerbate sleep disturbances, contributing to fatigue, irritability, and impaired
cognitive function. Sleep disruptions, reported by 40-60% of perimenopausal
and postmenopausal women, are further compounded by primary insomnia or
secondary causes such as mood disorders or sleep apnea, which become more
prevalent with age.
Mood and psychological symptoms are also significant, with 20-40% of
women experiencing increased anxiety, depression, or emotional lability during
perimenopause. Hormonal fluctuations, particularly rapid changes in estradiol,
influence neurotransmitter systems, including serotonin and gamma-
aminobutyric acid (GABA), which regulate mood and stress responses. Women
with a history of premenstrual syndrome or postpartum depression may be
particularly vulnerable, as these conditions suggest a heightened sensitivity to
hormonal shifts. Cognitive complaints, such as memory lapses or difficulty
concentrating (often termed “brain fog”), are reported by approximately 60% of
women, though longitudinal studies, such as the Study of Women’s Health
Across the Nation (SWAN), indicate that these effects are often transient and not
necessarily indicative of long-term cognitive decline. Genitourinary syndrome of
CURRENT APPROACHES AND NEW RESEARCH IN
MODERN SCIENCES
International scientific-online conference
101
menopause (GSM), encompassing vaginal dryness, dyspareunia, and urinary
symptoms like urgency or recurrent infections, affects up to 50% of
postmenopausal women. These symptoms result from estrogen deficiency,
which reduces vaginal epithelial thickness and lubrication, impairing sexual
function and increasing susceptibility to infections.
The long-term health implications of menopause are profound, driven
primarily by the loss of estrogen’s protective effects. Osteoporosis is a major
concern, as estrogen inhibits osteoclast activity, thereby maintaining bone
density. Post-menopause, bone resorption accelerates, leading to a 2-3% annual
bone loss in the first 5-7 years, particularly in trabecular bone sites like the
spine and hip. This increases the lifetime risk of osteoporotic fractures to 50%,
with hip fractures associated with significant morbidity and a 20-30% one-year
mortality rate in older women. Dual-energy X-ray absorptiometry (DEXA)
screening is recommended for women over 65 or younger with risk factors (e.g.,
smoking, low div weight, or family history) to assess bone mineral density and
guide preventive measures. Cardiovascular disease (CVD) risk also rises sharply,
as estrogen supports vasodilation, favorable lipid profiles (higher HDL, lower
LDL), and anti-inflammatory pathways. Postmenopausal women face a 2-3-fold
increased risk of coronary artery disease, with studies like the Framingham
Heart Study highlighting a shift toward atherogenic lipid profiles (elevated LDL
and triglycerides). Visceral fat accumulation, driven by hormonal and metabolic
changes, further elevates risks of metabolic syndrome, insulin resistance, and
type 2 diabetes, with 20-30% of postmenopausal women developing these
conditions.
Cancer risk profiles also shift post-menopause. While breast cancer risk is
influenced by cumulative estrogen exposure, the decline in endogenous estrogen
may slightly reduce risk in some women, though obesity and HRT use can
counteract this. Endometrial cancer risk decreases post-menopause due to the
cessation of unopposed estrogen stimulation, but women on estrogen-only HRT
(without progesterone) face an elevated risk of endometrial hyperplasia, a
precursor to cancer. Colorectal cancer risk, however, may increase slightly,
potentially due to changes in bile acid metabolism and gut microbiota influenced
by estrogen decline. Cognitive health remains an area of active research, with
conflicting evidence on menopause’s role in dementia risk. While some studies
suggest estrogen’s neuroprotective effects may mitigate Alzheimer’s disease
risk, others, including data from the Women’s Health Initiative Memory Study,
CURRENT APPROACHES AND NEW RESEARCH IN
MODERN SCIENCES
International scientific-online conference
102
indicate no clear protective effect of HRT on cognitive decline, underscoring the
complexity of hormonal influences on brain health.
Effective management of menopausal symptoms and long-term health risks
requires a tailored, evidence-based approach. Hormone replacement therapy
(HRT) is the gold standard for alleviating vasomotor symptoms and GSM, with
systemic estrogen (oral or transdermal) reducing hot flash frequency and
severity by 70-90%. For women with an intact uterus, combined estrogen-
progesterone therapy prevents endometrial hyperplasia. The Women’s Health
Initiative (WHI) clarified HRT’s risk-benefit profile: while effective for symptom
relief and fracture prevention, it carries risks, including a 26% increased breast
cancer risk and a 29% increased thromboembolism risk after five years of use.
Thus, guidelines recommend the lowest effective dose for the shortest duration,
typically initiated before age 60 or within 10 years of menopause to optimize
safety. Transdermal estrogen may offer a lower thromboembolism risk
compared to oral formulations. For women with contraindications (e.g., breast
cancer history or thrombophilia), non-hormonal options like low-dose
paroxetine (7.5 mg/day), a selective serotonin reuptake inhibitor, reduces hot
flashes by 40-60%. Gabapentin (300-900 mg/day) and clonidine (0.1 mg/day)
are alternatives, though less effective, with side effects like drowsiness limiting
their use.
Lifestyle interventions are foundational for both symptom management
and long-term health. Weight-bearing exercises (e.g., walking, resistance
training) reduce bone loss by stimulating osteoblast activity, while aerobic
exercise (150 minutes/week) improves cardiovascular health, mood, and weight
control. Dietary strategies emphasize calcium (1200 mg/day) and vitamin D
(800-1000 IU/day) for bone health, with fortified foods or supplements
recommended for deficient individuals. A Mediterranean diet, rich in omega-3
fatty acids, fiber, and antioxidants, supports lipid profiles and reduces
inflammation, mitigating CVD and diabetes risk. Smoking cessation is critical, as
tobacco exacerbates vasomotor symptoms and accelerates bone loss and CVD
risk. Alcohol moderation (≤1 drink/day) is advised to avoid exacerbating hot
flashes and breast cancer risk. Cognitive behavioral therapy (CBT) is highly
effective for managing mood disorders and insomnia, with randomized trials
showing 50-70% improvement in sleep quality and anxiety. Mindfulness-based
stress reduction (MBSR) and yoga further support emotional resilience and
sleep, with studies reporting 20-40% reductions in hot flash severity.
CURRENT APPROACHES AND NEW RESEARCH IN
MODERN SCIENCES
International scientific-online conference
103
Non-pharmacological and complementary therapies are increasingly
popular but require cautious evaluation. Phytoestrogens, such as soy
isoflavones, mimic estrogen’s effects but yield inconsistent results; meta-
analyses suggest a 10-20% reduction in hot flashes with high-dose isoflavones
(50-100 mg/day), though placebo effects are significant. Acupuncture shows
promise in small trials, reducing hot flash frequency by 30-50%, but large-scale,
high-quality studies are lacking. Herbal remedies like black cohosh are widely
used, yet systematic reviews find no consistent benefit, and rare cases of
hepatotoxicity raise safety concerns. Women must consult healthcare providers
to avoid herb-drug interactions, particularly with supplements like St. John’s
wort, which can affect antidepressant metabolism.
The genitourinary syndrome of menopause responds well to low-dose
vaginal estrogen (creams, rings, or tablets), which restores vaginal epithelium
with minimal systemic absorption, reducing risks associated with systemic HRT.
Non-hormonal vaginal moisturizers and lubricants provide symptomatic relief
for mild cases, while ospemifene, a selective estrogen receptor modulator, is an
oral option for dyspareunia, though it carries a small thromboembolism risk.
Regular sexual activity may also improve vaginal health by enhancing blood flow
and elasticity.
Psychosocial and cultural factors significantly shape the menopausal
experience. In cultures where aging is revered, such as in some Asian societies,
women report fewer or less severe symptoms compared to Western societies,
where menopause is often medicalized or stigmatized. Stigma can exacerbate
psychological distress, with 30-40% of women reporting feelings of loss or
diminished femininity. Support groups, peer counseling, and education can
mitigate these effects, fostering empowerment and reducing isolation. Shared
decision-making, where clinicians and patients collaboratively weigh treatment
options based on individual risk profiles, preferences, and values, enhances
treatment adherence and satisfaction. Decision aids and structured counseling
improve women’s understanding of risks, with studies showing a 20-30%
increase in treatment compliance when shared decision-making is employed.
Emerging research highlights novel therapeutic avenues. Neurokinin-3
receptor antagonists, such as fezolinetant, target the hypothalamic pathways
driving vasomotor symptoms, showing 60-80% reductions in hot flash
frequency in phase III trials. These agents offer a non-hormonal alternative with
fewer side effects than SSRIs or gabapentin. Advances in precision medicine,
including genetic profiling of estrogen metabolism pathways, may soon allow
CURRENT APPROACHES AND NEW RESEARCH IN
MODERN SCIENCES
International scientific-online conference
104
tailored HRT regimens to minimize risks like breast cancer. Wearable
technologies and mobile health apps are also gaining traction, enabling women
to track symptoms, sleep patterns, and lifestyle factors, providing data to guide
personalized interventions.
In conclusion, menopause is a multifaceted transition with immediate and
long-term implications for women’s health. Vasomotor symptoms, mood
disturbances, and genitourinary issues, while challenging, are manageable
through a combination of hormonal and non-hormonal therapies, lifestyle
modifications, and psychological support. Long-term risks, including
osteoporosis, cardiovascular disease, and metabolic disorders, underscore the
need for proactive prevention strategies. Cultural and individual variability
necessitates personalized care, supported by shared decision-making and
emerging therapeutic innovations. By integrating evidence-based interventions
with holistic support, women can navigate menopause with resilience,
maintaining health and well-being into later life.
References:
1.
North American Menopause Society. (2022). The 2022 Hormone Therapy
Position Statement of The North American Menopause Society. Menopause,
29(7), 767-794.
2.
Santoro, N., Epperson, C. N., & Mathews, S. B. (2015). Menopausal
symptoms and their management. Endocrinology and Metabolism Clinics of
North America, 44(3), 497-515.
3.
Davis, S. R., Lambrinoudaki, I., Lumsden, M., et al. (2015). Menopause.
Nature Reviews Disease Primers, 1, 15004.
4.
Nelson, H. D. (2008). Menopause. The Lancet, 371(9614), 760-770.
5.
Rossouw, J. E., Anderson, G. L., Prentice, R. L., et al. (2002). Risks and
benefits of estrogen plus progestin in healthy postmenopausal women: Principal
results from the Women’s Health Initiative randomized controlled trial. JAMA,
288(3), 321-333.
6.
Crandall, C. J., Aragaki, A. K., Cauley, J. A., et al. (2018). Associations of
menopausal vasomotor symptoms with fracture incidence. Journal of Clinical
Endocrinology & Metabolism, 103(2), 562-570.
7.
Thurston, R. C., & Joffe, H. (2011). Vasomotor symptoms and menopause:
Findings from the Study of Women’s Health Across the Nation. Obstetrics and
Gynecology Clinics of North America, 38(3), 489-501.
